Table 1 Baseline characteristics
Entire cohort (n = 58) | First-line cohort (n = 44) | Later-line cohort (n = 14) | |
|---|---|---|---|
Setting, n (%) | |||
First-line treatment Second-line treatment Third-line treatment Fourth-line treatment | 44 (75.9) 10 (17.3) 2 (3.4) 2 (3.4) | 44 (100) - - - | - 10 (71.4) 2 (14.3) 2 (14.3) |
Sex, n (%) | |||
Female Male | 10 (17.2) 48 (82.8) | 7 (15.9) 37 (84.1) | 3 (21.4) 11 (78.6) |
Age, mean (SD), years | 54.5 (9.1) | 53.9 (9.1) | 56.4 (9.3) |
BMI, median (IQR), kg/m2 | 22.2 (19.8,24.7) | 22.5 (20.1,24.7) | 21.2 (19.9,24.2) |
Health care system, n (%) | |||
CSMBS Social security Universal coverage Self-payment | 7 (12.1) 7 (12.1) 40 (69.0) 4 (6.9) | 4 (9.1) 7 (15.9) 32 (72.7) 1 (2.3) | 3 (21.4) 0 (0) 8 (57.1) 3 (21.4) |
ECOG, n (%) | |||
0 1 2 | 8 (13.8) 48 (82.8) 2 (3.4) | 5 (11.4) 38 (86.4) 1 (2.3) | 3 (21.4) 10 (71.4) 1 (7.1) |
Cirrhosis, n (%) | 53 (91.4) | 40 (90.9) | 13 (92.9) |
CTP score, n (%) | |||
A B | 42 (72.4) 16 (27.6) | 31 (70.4) 13 (29.6) | 11 (78.6) 3 (21.4) |
Etiology, n (%) (* more than 1 answer) | |||
HBV HCV Alcohol NAFLD PSC | 42 (72.4) 9 (15.5) 8 (13.8) 2 (3.4) 1 (1.7) | 31 (70.5) 6 (13.6) 8 (18.2) 1 (2.3) 1 (2.3) | 11 (78.6) 3 (21.4) 0 (0) 1 (7.1) 0 (0) |
Number of liver tumors, n | |||
(%) 0 1–5 6–10 > 10 Infiltrative | 7 (12.1) 27 (46.5) 3 (5.2) 18 (31.0) 3 (5.2) | 4 (9.1) 21 (47.7) 1 (2.3) 15 (34.1) 3 (6.8) | 3 (21.4) 6 (42.9) 2 (14.3) 3 (21.4) 0 (0) |
Maximum diameter of tumor, mean (SD), cm | 11.1 (6) | 11.2 (5.7) | 10.7 (7.1) |
Vascular involvement, n (%) | 33 (56.9) | 27 (61.4) | 6 (42.9) |
Ascites, n (%) | 7 (12.1) | 5 (11.4) | 2 (14.3) |
BCLC stage, n (%) | |||
B C | 7 (12.1) 51 (87.9) | 5 (11.4) 39 (88.6) | 2 (14.3) 12 (85.7) |
Extrahepatic metastasis, | |||
n (%) 1 2 3 4 | 21 (36.2) 8 (13.8) 1 (1.7) 1 (1.7) | 17 (38.6) 4 (9.1) 0 (0) 0 (0) | 4 (28.6) 4 (28.6) 1 (7.1) 1 (7.1) |
Metastatic site, n (%) | |||
Lymph node Lung Pleura Peritoneum Adrenal Bone Ovary Pancreas | 13 (22.4) 15 (25.9) 2 (3.4) 8 (13.8) 2 (3.4) 2 (3.4) 1 (1.7) 1 (1.7) | 7 (15.9) 8 (18.2) 0 (0) 6 (13.6) 1 (2.3) 1 (2.3) 1 (2.3) 1 (2.3) | 6 (42.9) 7 (50.0) 2 (14.3) 2 (14.3) 1 (7.1) 1 (7.1) 0 (0) 0 (0) |
ALBI score, n (%) | |||
1 2 3 | 12 (20.7) 39 (67.2) 7 (12.1) | 8 (18.2) 30 (68.2) 6 (13.6) | 4 (28.6) 9 (64.3) 1 (7.1) |
Lab | |||
TBIL, median (IQR), mg/dL AST, median (IQR), U/L ALT, median (IQR), U/L ALP, median (IQR), U/L Albumin, mean (SD), g/dL Platelet count, median (IQR), /uL INR, median (IQR) Creatinine, median (IQR), mg/dL AFP, median (IQR), ng/dL | 1.2 (0.7,1.7) 98 (57.8,230.5) 45 (30.8,77.0) 235(148.5,386.2) 3.5 (0.5) 209,000 (130750,260750) 1.2 (1.2,1.4) 0.8 (0.6,1) 6056(265,30103) | 1.2 (0.7,1.7) 112 (61.5,280.5) 48 (29.8,76.0) 257.5(152.2,393.2) 3.5 (0.5) 211,000 (125000,269750) 1.3 (1.2,1.4) 0.8 (0.6,1) 5630.5(443,28734) | 1.1 (0.6,1.9) 78.5 (49.5,109.5) 42.5 (33.0,71.0) 203 (77.5,256) 3.7 (0.5) 189,250 (139250,250000) 1.2 (1.1,1.2) 0.8(0.6,0.8) 24007.5(197,36309) |
Prior treatment, n (%) | |||
Resection TACE RFA SBRT Doxorubicin Sorafenib Regorafenib Nivolumab Atezolizumab/Bevacizumab Durvalumab/Tremelimumab | 10 (17.2) 21 (36.2) 5 (8.6) 2 (3.4) 2 (3.4) 11 (19.0) 2 (3.4) 2 (3.4) 1 (1.7) 2 (3.4) | 4 (9.1) 14 (31.8) 5 (11.4) 2 (4.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) | 6 (42.9) 7 (50) 0 (0) 0 (0) 2 (14.3) 11 (78.6) 2 (14.3) 2 (14.3) 1 (7.1) 2 (14.3) |